Unapproved Drugs in Androgen Receptor Modulators Sold Online

Share this content:
Growth hormone secretagogue ibutamoren was one unapproved drug found in online marketed products.
Growth hormone secretagogue ibutamoren was one unapproved drug found in online marketed products.

HealthDay News — Products marketed as selective androgen receptor modulators and sold via the internet frequently contain unapproved drugs and substances, and the amount of active compound often does not match that listed on the label, according to a study in the Journal of the American Medical Association.

Ryan M. Van Wagoner, PhD, from the Sports Medicine Research and Testing Laboratory in Salt Lake City, and colleagues analyzed the chemical identity and amounts of ingredients in dietary supplements and products that are marketed and sold via the internet as selective androgen receptor modulators.

The researchers found that 23 of the 44 products marketed and sold as selective androgen receptor modulators contained one or more selective androgen receptor modulator. Another unapproved drug was identified in an additional 17 products, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Four products had no active compound, and 11 contained substances not listed on the label. The amount of active compound in the product matched that listed on the label in 18 of the products. In 26 of the products, the quantity of the compounds listed on the label differed substantially from that found by analysis.

"In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances," the authors write. "Only 52% contained selective androgen receptor modulators and many were inaccurately labeled."

One author disclosed financial ties to the pharmaceutical industry.

Reference

Richard J. Auchus, Kirk J. Brower. The Public Health Consequences of Performance-Enhancing Substances Who Bears Responsibility?. JAMA. 2017 Nov 28. doi:10.1001/jama.2017.17111

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters